Market revenue in 2023 | USD 712.2 million |
Market revenue in 2030 | USD 1,392.2 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Product registration & clinical trial applications |
Fastest growing segment | Legal representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory consulting, Legal representation, Regulatory writing & publishing, Product registration & clinical trial applications, Regulatory Submissions, Regulatory Operations, Other services |
Key market players worldwide | Genpact Ltd, Criterium Inc., Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, Labcorp Drug Development, FREYR Battery Inc, Cencora Inc, Pharmexon, QVigilance, BlueReg Group, ZEINCRO Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs outsourcing market will help companies and investors design strategic landscapes.
Product registration & clinical trial applications was the largest segment with a revenue share of 25.99% in 2023. Horizon Databook has segmented the China regulatory affairs outsourcing market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, other services covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most attractive markets for the biopharmaceutical industry. The growing geriatric population and the presence of a large pool of population belonging to the middle-income group are further increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical device companies in this region.
Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies as a clinical trial application process requires 12 to 24 months while the approval process may require more than six years.
Along with national approvals, the new drug requires approval at both the provincial or city levels, which may require an additional four to five years. Reforms in the healthcare sector in recent times are expected to streamline the approval process.
Horizon Databook provides a detailed overview of country-level data and insights on the China regulatory affairs outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into China regulatory affairs outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account